0.1366

0.65% -0.0009

Pre-market: .14 0.0034 +2.49%

Akari Therapeutics Plc Adr (AKTX)

Overview News Price History Financials Discussions Forecast Stock Split

Akari Therapeutics Plc Adr stock is traded at $0.1366, with a volume of 246.46K. It is down -0.65% in the last 24 hours and down -47.64% over the past month. Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

Previous Close:

$0.1375

Open:

$0.145909

24h Volume:

246.46K

Relative Volume:

0.38

Market Cap:

$6.25M

Revenue:

Net Income/Loss:

$-15.72M

P/E Ratio:

-0.349

EPS:

-0.3914

Net Cash Flow:

$-9.68M

1W Performance:

-15.99%

1M Performance:

-47.64%

6M Performance:

-87.80%

1Y Performance:

-90.64%

1-Day Range:

$0.1348

$0.1459

1-Week Range:

$0.13

$0.1676

52-Week Range:

$0.13

$1.58

Akari Therapeutics Plc Adr Stock (AKTX) Company Profile

Name

Akari Therapeutics Plc Adr

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

(929) 274-7510

Address

401 EAST JACKSON STREET, TAMPA

Employee

Twitter

@AkariTX

Next Earnings Date

2026-04-15

Latest SEC Filings

AKTX's Discussions on Twitter

Compare AKTX vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AKTX Akari Therapeutics Plc Adr	0.1366	6.30M	0	-15.72M	-9.68M	-0.3914
VRTX Vertex Pharmaceuticals Inc	454.97	115.58B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	79.23B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	43.59B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	43.26B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	31.97B	606.42M	-1.28B	-997.58M	-6.403

Akari Therapeutics Plc Adr Stock (AKTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-05-26	Initiated	Ladenburg Thalmann	Buy
Jul-18-25	Initiated	Maxim Group	Buy
Jan-04-19	Upgrade	B. Riley FBR	Neutral → Buy
Feb-08-18	Initiated	B. Riley FBR, Inc.	Neutral
Sep-22-17	Upgrade	William Blair	Mkt Perform → Outperform
May-31-17	Upgrade	Chardan Capital Markets	Sell → Neutral
Apr-17-17	Reiterated	Chardan Capital Markets	Sell
Jul-11-16	Initiated	Chardan Capital Markets	Sell

View All

Akari Therapeutics Plc Adr Stock (AKTX) Latest News

Mar 19, 2026

Get insights into the top gainers and losers of Thursday's after-hours session. - ChartMill

Mar 19, 2026

Mar 17, 2026

Akari Therapeutics adjusts ADS ratio to meet Nasdaq rules By Investing.com - Investing.com India

Mar 17, 2026

Akari Therapeutics adjusts ADS ratio to meet Nasdaq rules - Investing.com South Africa

Mar 17, 2026

Stay updated with the stocks that are on the move in today's after-hours session. - ChartMill

Mar 17, 2026

Akari Therapeutics (NASDAQ: AKTX) plans 1-for-40 ADS ratio change to meet Nasdaq bid rules - Stock Titan

Mar 17, 2026

Akari Therapeutics Announces ADS Ratio Change - Sahm

Mar 17, 2026

Mar 16, 2026

Director Neal James acquires Akari (AKTX) ADS warrants via placement and note swap - Stock Titan

Mar 16, 2026

Mar 13, 2026

Akari Therapeutics marks one year under CEO Gaslightwala By Investing.com - Investing.com India

Mar 13, 2026

Akari Therapeutics marks one year under CEO Gaslightwala - Investing.com

Mar 13, 2026

Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala - Sahm

Mar 13, 2026

Mar 02, 2026

Akari Therapeutics (AKTX) investors approve multiple warrant exercisability resolutions - Stock Titan

Mar 02, 2026

Feb 26, 2026

Akari Therapeutics adds Dana-Farber expert to advisory board - Investing.com

Feb 26, 2026

Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board - Finviz

Feb 26, 2026

Feb 23, 2026

Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board - ChartMill

Feb 23, 2026

Feb 18, 2026

Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference - Sahm

Feb 18, 2026

Feb 14, 2026

Will Akari Therapeutics Plc Depositary Receipt outperform the market in YEAR2025 Earnings Impact & Free High Return Stock Watch Alerts - mfd.ru

Feb 14, 2026

Feb 11, 2026

Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company’s Expanded ADC Pipeline - ChartMill

Feb 11, 2026

Feb 05, 2026

Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - Sahm

Feb 05, 2026

Feb 03, 2026

Akari Therapeutics (NASDAQ: AKTX) seeks approval for major warrant exercises - Stock Titan

Feb 03, 2026

Jan 26, 2026

Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors - Sahm

Jan 26, 2026

Jan 12, 2026

Curious about the stocks that are showing activity after the closing bell on Monday? - Chartmill

Jan 12, 2026

Jan 09, 2026

Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026 - GlobeNewswire Inc.

Jan 09, 2026

Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026 - Sahm

Jan 09, 2026

Akari Therapeutics to Present at the 2026 Biotech Showcase - Sahm

Jan 09, 2026

Dec 31, 2025

Why Vanda Pharmaceuticals Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Sahm

Dec 31, 2025

Dec 30, 2025